Page last updated: 2024-11-10

glycodeoxycholic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Glycodeoxycholic Acid: A bile salt formed in the liver by conjugation of deoxycholate with glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and choleretic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glycodeoxycholic acid : A bile acid glycine conjugate of deoxycholic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID3035026
CHEMBL ID258605
CHEBI ID27471
SCHEMBL ID24841
MeSH IDM0009457

Synonyms (46)

Synonym
CHEBI:27471 ,
gdca
n-((3-alpha,5-beta,12-alpha)-3,12-dihydroxy-24-oxocholan-24-yl)-glycine
glycine, n-(3-alpha,12-alpha-dihydroxy-5-beta-cholan-24-yl)-
glycine, n-((3alpha,5beta,12alpha)-3,12-dihydroxy-24-oxocholan-24-yl)-
deoxycholylglycine
glykodesoxycholsaeure [german]
5-beta-cholan-24-oic acid, glycodeoxy-
glycodesoxycholic acid
C05464
3alpha,12alpha-dihydroxy-5beta-cholan-24-oylglycine
glycodeoxycholic acid
SPECTRUM5_002013
G-5420
GLYCODEOXYCHOLIC_ACID ,
CHEMBL258605 ,
BMSE000644
2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
n-(3alpha,12alpha-dihydroxy-5beta-cholan-24-oyl)glycine
LMST05030006
ds124m0828 ,
glykodesoxycholsaeure
unii-ds124m0828
bdbm50375587
glycine, n-[(3a,5b,12a)-3,12-dihydroxy-24-oxocholan-24-yl]-
2-[(4r)-4-[(1s,2s,5r,7r,10r,11s,14r,15r,16s)-5,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]acetic acid
gtpl4714
BRD-K68144790-001-01-2
SCHEMBL24841
AKOS025290392
deoxyglycocholic acid
glycine, n-(3.alpha.,12.alpha.-dihydroxy-5.beta.-cholan-24-oyl)-
glycyldeoxycholic acid
5.beta.-cholan-24-amide, n-(carboxymethyl)-3.alpha.,12.alpha.-dihydroxy-
cholane, glycine deriv.
glycine, n-[(3.alpha.,5.beta.,12.alpha.)-3,12-dihydroxy-24-oxocholan-24-yl]-
3.alpha.,12.alpha.-dihydroxy-5.beta.-cholanic acid-24-glycine
glycine, n-((3.alpha.,5.beta.,12.alpha.)-3,12-dihydroxy-24-oxocholan-24-yl)-
n-(3alpha,12alpha-dihydroxy-5beta-cholan-24-oyl)-glycine
glykodesoxycholsaure
HY-125731
Q5572601
F20550
n-[(3alpha,5beta,12alpha)-3,12-dihydroxy-24-oxocholan-24-yl]glycine
STL565143
CS-0093438

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The coupling of cell colonies with a suitable transduction device has led to the development in recent years of toxicity biosensors based on the alteration of a process or a cell metabolic function by the toxic substance under examination."( Toxicity order of cholanic acids using an immobilised cell biosensor.
Campanella, L; Favero, G; Mastrofini, D; Tomassetti, M, 1996
)
0.29
" Finally, CDCA, DCA and LagoDCA were prominent outliers being more toxic than predicted by RMw."( Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
Gilmer, JF; Keaveney, R; Kelleher, D; Long, A; Majer, F; Peta, VK; Sharma, R; Wang, J, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters AUC (relative bioavailability) and c(max) of quinine were significantly decreased by micellar systems in rabbits."( The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits.
Dongowski, G; Fritzsch, B; Giessler, J; Härtl, A; Kuhlmann, O; Neubert, RH, 2005
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" reuteri on the bioavailability of isoflavones present in soygerm powder was examined."( Combined use of Lactobacillus reuteri and soygerm powder as food supplement.
De Boever, P; Verstraete, W; Wouters, R, 2001
)
0.31
"The bioavailability of orally administered drugs can be influenced by interactions with food components and by physico-chemical conditions in the upper gastrointestinal tract."( The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits.
Dongowski, G; Fritzsch, B; Giessler, J; Härtl, A; Kuhlmann, O; Neubert, RH, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Activities of AST in treated guinea pigs were significantly higher than those in controls for only 2 dosage levels (0."( Serum concentration of bile acids in guinea pigs as an indicator of liver damage caused by aflatoxins.
Baetz, AL; McLoughlin, ME, 1983
)
0.27
" Thus, in this work, a dose-response study was carried out to investigate the in vitro cytotoxic effect of major unconjugated and tauro- (T) or glyco- (G) conjugated bile acids and to compare this as regards their ability to inhibit DNA synthesis."( Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture.
Marin, JJ; Martinez-Diez, MC; Monte, MJ; Serrano, MA, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
bile acid glycine conjugateAmide of a bile acid with glycine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)1.18000.02372.52598.9000AID324923
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 1A5Rattus norvegicus (Norway rat)Km4.30004.30006.39608.8000AID681360
Ileal sodium/bile acid cotransporterHomo sapiens (human)Km2.00002.00005.30009.4000AID678823
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
sodium ion transportIleal sodium/bile acid cotransporterHomo sapiens (human)
response to bacteriumIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid and bile salt transportIleal sodium/bile acid cotransporterHomo sapiens (human)
transmembrane transportIleal sodium/bile acid cotransporterHomo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
protein bindingIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid:sodium symporter activityIleal sodium/bile acid cotransporterHomo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
microvillusIleal sodium/bile acid cotransporterHomo sapiens (human)
apical plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID681360TP_TRANSPORTER: uptake in Oatp3-expressing MDCK cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID678823TP_TRANSPORTER: uptake in ASBT-expressing COS cells1998The American journal of physiology, 01, Volume: 274, Issue:1
Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
AID681361TP_TRANSPORTER: uptake in Oatp3-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID681349TP_TRANSPORTER: uptake in ASBT-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID680634TP_TRANSPORTER: inhibition of BSP uptake (BSP: 2 uM, GDCA: 100 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID680254TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 20 uM, GDCA: 200 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID515399Cytotoxicity against human HuH7 cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID515397Cytotoxicity against human HET-1A cells assessed as cell viability at >1 mM after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID515400Cytotoxicity against human HET-1A cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID515398Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (181)

TimeframeStudies, This Drug (%)All Drugs %
pre-199051 (28.18)18.7374
1990's48 (26.52)18.2507
2000's38 (20.99)29.6817
2010's30 (16.57)24.3611
2020's14 (7.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.74 (24.57)
Research Supply Index5.25 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.53%)0.25%
Other189 (99.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]